CC
ASMB icon

Commodore Capital’s Assembly Biosciences ASMB Stock Holding History

Commodore Capital’s Portfolio ASMB Stock Details ASMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$38.9M Buy
1,415,000
+415,000
+42% +$11.3M 2.32% 16
2026
Q1 		$27.8M Hold
1,000,000
– – 1.61% 21
2025
Q4 		$34M Hold
1,000,000
– – 2.26% 18
2025
Q3 		$25.6M Buy
+1,000,000
New +$21.9M 1.25% 25

Other funds holding ASMB

GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PHP
Parkman Healthcare Partners Stamford, Connecticut $977M AUM 110.37% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
SFCM
Seven Fleet Capital Management Mountain View, California $606M AUM

Commodore Capital's ASMB Position: Q2 2026 in Review

Commodore Capital increased its Assembly Biosciences (ASMB) stake by 42% in Q2 2026, buying an estimated $11.3M and bringing the position to 1,415,000 shares worth $38.9M. The position accounts for 2.32% of the portfolio, ranked #16.

Commodore Capital first reported a position in ASMB in Q3 2025 and has held it in 4 quarters since. 93 funds tracked by Wall St. Rank hold ASMB as of Q2 2026.

  • Commodore Capital held 1,415,000 shares of Assembly Biosciences worth $38.9M as of Q2 2026.
  • Commodore Capital bought 415,000 Assembly Biosciences shares in Q2 2026, an estimated $11.3M.
  • Assembly Biosciences made up 2.32% of Commodore Capital's portfolio in Q2 2026, its #16 holding.
  • Commodore Capital first reported a position in Assembly Biosciences in Q3 2025 and has held it in 4 quarters since.
  • 93 funds tracked by Wall St. Rank held Assembly Biosciences as of Q2 2026.

Based on Commodore Capital's 13F filing for Q2 2026, filed 14 Aug 2026.